Coronary heart disease is the leading cause of death in the Western world. Antithrombotic therapy is the cornerstone of its successful treatment. Clinical trials have demonstrated that antithrombotic therapy reduces the risk for recurrent myocardial infarction and cardiovascular death. Antiplatelet drugs and anticoagulants interfere with haemostasis and thus bleeding is a major risk factor of these drugs. The benefit of antithrombotic therapy must therefore be carefully balanced with the risk of bleeding and other potential adverse reactions of these drugs. However, to date there is no firm evidence that dosage adaptation of aspirin or clopidogrel according to platelet aggregation testing translates directly into any clinical benefit. Resistance to antithrombotic drugs is a serious problem because these patients are at a higher risk of myocardial infarction, stroke and cardiovascular death. It has most recently been demonstrated that resistance to clopidogrel is at least in part caused by polymorphism of CYP2C19. Clinical trials have also demonstrated that optimal benefit in different settings depends unequivocally on the meticulous choice of the various drugs. Thus, profound knowledge of the clinical pharmacological profiles of the different antithrombotic drugs is indispensable for successful treatment.
Antiplatelet agents
The physiology of platelet aggregation has recently been reviewed [Furie and Furie, 2008; Davi and Patrono, 2007] . In the normal physiological state platelets are maintained inactive by nitric oxide and prostacycline synthesized by endothelial cells in response to shear stress. However, if the endothelial cell layer is damaged the synthesis of these mediators is impaired and subendothelial matrix is exposed. Platelets adhere to exposed collagen, von Willebrand factor (vWF) and fibronectin via different integrins. Adherent platelets undergo shape changes, synthesize de novo thromboxane and secrete ADP from granules. Thromboxane intensifies platelet aggregation by slowing blood flow and direct stimulation of platelet aggregation. Binding of ADP to the P2Y 12 -receptor stimulates the intracellular signal transduction chain and finally initiates a conformational change of the glycoprotein (GP) IIb/IIIa-receptors. Fibrinogen binds to activated GP IIb/IIIa-receptors and crosslinks platelets with each other. This stabilizes the primary thrombus and allows the build-up of larger platelet aggregates. However, this fibrinogen platelet mesh is still unstable. Phospholipidcomplexes on the surface of activated platelets as well as Ca 2+ liberation are essential components of triggering the coagulation pathway. Contact with tissue factor from the injured vascular tissue starts the coagulation cascade and finally converts prothrombin to thrombin. Thrombin is not only one of the most potent stimulators of platelet aggregation but also catalyses proteolysis from fibrinogen to fibrin and thereby transfers the unstable primary plug into a stable secondary plug. However, for successful treatment of acute coronary syndrome, thrombus formation and stabilization must be prevented by antithrombotic drugs [Pollack and Goldberg, 2008; Duvall, 2006; Blann et al. 2002] (Figure 1 ).
Acetylsalicylic acid (aspirin) was the first drug used routinely to prevent atherothrombosis [Patrono et al. 2005] . Thromboxane, the sole metabolite of cyclo-oxygenase I (COX I) synthesized in platelets, is a potent vasoconstrictor and a stimulator of platelet aggregation. Aspirin acts by an irreversible acetylation of COX I and therefore blocks the synthesis of this important stimulator of platelet aggregation [Patrono et al. 2008] . It inhibits also the synthesis of prostacylin (PGI 2 ), a potent vasodilator and inhibitor of platelet aggregation, which is mainly synthesized by endothelial cells. However, in contrast to platelets, endothelial cells are able to synthesize new COX I within a few hours and thus restore PGI 2 synthesis. From this it follows that aspirin selectively blocks platelet aggregation. Normally it takes 57 days until new platelets from bone marrow have restored the blocked older platelets. As aspirin only inhibits thromboxane synthesis and does not affect other potent stimulators of platelet aggregation such as ADP or collagen, it is a weak antiplatelet agent. Absorption of low-dose aspirin depends upon the formulation used. Plain aspirin is absorbed rapidly and completely while absorption of enteric-coated formulations is more variable. Aspirin is subject to rapid and intensive first pass metabolism. Therefore, after oral intake of low-dose aspirin no measurable amounts of aspirin can be detected in plasma. The half-life of aspirin is approximately 20 min and its main metabolite is salicylic acid which is only a weak reversible inhibitor of COX I. Salicylic acid has a half-life of approximately 6 hours. It is further metabolized and mainly excreted by the kidney. The antiplatelet effect of aspirin starts 1015 min after oral administration. For full effectiveness thromboxane synthesis must be blocked by more than 95%. Due to the irreversible inhibition of COX I low-dose aspirin (75150 mg/day) cumulates and after 35 days full response is achieved. To achieve an immediate clinical antithrombotic effect, an initial minimum loading dose of a 162 mg (or better 325 mg) tablet of aspirin should be chewed and swallowed [Hennekens et al. 1997; Reeder, 1995] . In some European countries aspirin is available as an intravenous formulation (aspirinlysine). A bolus of 300500 mg aspirinlysine is recommended to achieve an immediate antithrombotic effect. The most serious adverse drug reaction of aspirin is gastrointestinal bleeding. Chronic daily intake of low doses of aspirin (85325 mg) increases the risk of upper gastrointestinal events by two-to four-fold [Yeomans et al. 2005; Weil et al. 1995] . Enteric coated or buffered drug formulations do not reduce the risk of bleeding [De Abajo and Garcia Rodriguez, 2001; Kelly et al. 1996] . Concomitant treatment with a protein pump inhibitor (PPI) has been shown to reduce the risk for bleeding in the upper gastrointestinal tract but not in the lower gastrointestinal tract. The prevalence of aspirin sensitivity in asthmatic adults is approximately 1015% and doubles in patients with nasal polyps [Szczeklik and Stevenson, 2003; Banks et al. 1994 ]. Furthermore, the prevalence of aspirin-induced urticaria and angioedema is 0.10.3% in the general population [Sanchez-Borges et al. 2002] . However, this risk increases to 2130% of patients with chronic urticaria [Sanchez-Borges et al. 2002] . Bleeding due to concomitant use of aspirin and anticoagulants especially warfarin is the most often reported drug interaction. Therapeutic Advances in Cardiovascular Disease 3 (6)
The concomitant use of aspirin and warfarin increases the risk for a clinical significant bleeding by 2.75 compared with monotherapy [Johnson et al. 2008] . Therefore this combination should be restricted to patients who meet evidencebased criteria. Drug interactions between NSAIDs and aspirin are obvious because both inhibit cyclo-oxygenase. The interaction of ibuprofen with aspirin is of clinical importance because this over-the-counter NSAID abrogates any inhibitory effect of aspirin on platelet aggregation after 34 days [Gengo et al. 2008] . The concomitant use of NSAIDs and aspirin increases the risk for gastrointestinal bleeding. Additional risk factors are chronic alcohol use and concomitant therapy with corticosteroids. A number of drugs such as phenytoin or rifampicin can decrease the efficacy of aspirin by inducing hepatic enzymes to metabolize aspirin. Bioavailability of aspirin from enteric coated or buffered drug formulation is reduced if antacids or PPIs are used concomitantly. Aspirin is contraindicated in patients with active erosive gastritis or peptic ulceration or previous intracranial haemorrhage. It should be withdrawn 57 days before elective major surgery except where the antithrombotic benefits of aspirin substantially outweigh the potential risk of perioperative bleeding. For most dental procedures it is unnecessary to interrupt aspirin treatment. Aspirin is contraindicated in patients who are intolerant to aspirin or NSAIDs. Because of the association with Reye's syndrome, the use of aspirin in children including teenagers with flu-like symptoms is contraindicated. It is also contraindicated during the third trimester of pregnancy because it can lead to a prolongation of gestation, inhibits uterine contractions, increases bleeding at birth and promotes premature closure of the arterial duct. It should be used cautiously within the first and second trimester of pregnancy because malformations (FDA Category D) have been reported, though with higher dosages of aspirin. The recently updated evidence-based guidelines of the American College of Cardiology/American Heart Association recommend the use of aspirin for unstable angina (UA), non-ST elevation myocardial infarction (NSTEMI) and ST-elevation myocardial infarction (STEMI) as well as in secondary prophylaxis King et al. 2008; Anderson et al. 2007; Fraker et al. 2007 ].
Thienopyridines
The thienopyridines ticlopidine [McTavish et al. 1990; Saltiel and Ward, 1987] and clopidogrel [Jarvis and Simpson, 2000] are structurally related compounds that highly selective bind to the P2Y 12 -receptor on the surface of platelets. This binding is irreversible and therefore platelets exposed to thienopyridines are inhibited for their life spans. Thienopyridines block ADP-induced platelet aggregation only and have little effect on other agonists of platelet aggregation. Both drugs are inactive prodrugs that must be metabolized by the hepatic CYP-450 enzyme system to an active substance. Because ticlopidine is associated with a higher incidence of adverse events clopidogrel has become the drug of choice. Clopidogrel [Patrono et al. 2008] is rapidly absorbed from the gastrointestinal tract with a bioavailability of about 50%. It is 98% bound to plasma proteins. Clopidogrel undergoes extensive hepatic metabolism to its active metabolite, a carboxylic acid derivative. The half-life of this active metabolite is approximately 8 hours. The effect of liver disease on antiplatelet activity of clopidogrel has not been thoroughly investigated.
After repeated daily dosing of 75 mg clopidogrel, a steady state is achieved after 47 days. If a more rapid antiplatelet effect is required a loading dose of 300 mg clopidogrel followed by a daily dose of 75 mg is needed. Higher loading doses such as 600 or 900 mg are currently under investigation.
In the steady state, clopidogrel inhibits 5060% of ADP induced platelet aggregation. Because clopidogrel-induced inhibition of platelet function is irreversible it takes 57 days to restore platelet function completely. This must be considered if clopidogrel is used in patients who will be invasively treated. Severe rash and diarrhoea were more frequently associated with clopidogrel than with aspirin. The incidence of haemorrhagic events was comparable between aspirin and clopidogrel. Gastrointestinal bleeding occurs with both aspirin and clopidogrel. However, substitution of clopidogrel for aspirin in high-risk patients with recurrent ulcer bleeding is not recommended because it is inferior to treatment with aspirin and a PPI [Bhatt et al. 2008] . A serious but less frequent adverse reaction of clopidogrel is intracranial haemorrhage. Clopidogrel was associated with thrombotic thrombocytopenic purpura (TTP) [Bennett et al. 2000 ]. Neutropenia and TTP were similar in aspirin and clopidogrel. TTP occurs within the first 2 weeks of treatment. Ticlopidine is associated with neutropenia in approximately 1%, which is mostly reversible on discontinuation of therapy. However, in a few cases it is irreversible and potentially life threatening. Patients must therefore be regularly monitored within the first 3 months of treatment. Clopidogrel is contraindicated in patients hypersensitive to ticlopidine, with active gastrointestinal bleeding, acute haemorrhagic stroke and severe hepatic impairment. Clopidogrel is associated with an increased risk of bleeding. This is especially a problem with patients undergoing percutaneous coronary intervention (PCI) or bypass surgery. The risk of reoperation and requirement of blood transfusions during coronary bypass operation is increased. Clopidogrel should be discontinued 7 days before elective surgery if an antiplatelet effect is not desired (prescribing information of the manufacturer). The concurrent use of clopidogrel with other platelet inhibitors, anticoagulants, fibrinolytics or NSAIDs is associated with an increased incidence of bleeding. To reduce the risk for gastrointestinal bleeding guidelines recommend the add-on use of a PPI. However, a recent trial has shown that certain PPIs (namely omeprazole, lansoprazole or rabeprazole) interfere with the activating metabolism of clopidrogrel [Juurlink et al. 2009 ]. This results in a decrease of the antiplatelet activity of clopidogrel and patients treated with one of these PPI were at a significant higher risk for readmission for MI. The recently updated evidence-based guidelines of the American College of Cardiology/American Heart Association recommend the use clopidogrel for unstable angina (UA), non-ST elevation myocardial infarction (NSTEMI) and STelevation myocardial infarction (STEMI) as well as in secondary prophylaxis King et al. 2008; Anderson et al. 2007; Fraker et al. 2007 ].
Dual antiplatelet therapy
Because aspirin and clopidogrel have completely different mechanisms of action it makes sense to combine these two drugs to improve effectiveness and safety. Clinical trials have demonstrated that the combination of aspirin and clopidogrel is more effective in reducing thrombotic events than aspirin alone. However, the risk for bleeding increases with this combination. This was confirmed in a recent meta-analysis that showed that the combination of aspirin and clopidogrel reduces the risk for cardiovascular events in patients with acute coronary syndromes or who undergo PCI [Bowry et al. 2008 ]. This analysis also shows that this benefit is associated with significantly increased risk of major bleeding. The recently updated evidence based guidelines for unstable angina/NSTEMI of the American College of Cardiology/American Heart Association recommend the dual use of clopidogrel and aspirin after implantation of a stent [Anderson et al. 2007] . For patients treated with bare-metal stents, aspirin 162325 mg/day should be prescribed for at least 1 month, then continued indefinitely at a dose of 75162 mg/ day; clopidogrel should be prescribed at a dose of 75 mg/day for a minimum of 1 month and ideally for up to 1 year. For patients with an increased bleeding risk clopidogrel should be given for a minimum of 2 weeks.
For patients treated with drug-eluting stents (DES), aspirin 162325 mg/day should be prescribed for at least 3 months after sirolimus-eluting stent implantation and 6 months after paclitaxel-eluting stent implantation, then continued indefinitely at a dose of 75162 mg/day. Clopidogrel 75 mg daily should be given for at least 12 months to all post-PCI patients receiving DES [Anderson et al. 2007] .
Second-generation thienopyridines
The second-generation thienopyridines prasugrel and cangrelor are new drugs which also bind to P2Y 12 -receptor like the first generation but they differ greatly with respect to their pharmacokinetic properties. Prasugrel is structurally related to the other thienopyridines [Angiolillo et al. 2008a; 2008b] . It irreversibly binds to the P2Y 12 -receptor and blocks ADP-induced platelet aggregation. In contrast to clopidogrel, prasugrel is rapidly de-esterified to an intermediate which is then metabolized by a CYP-450 dependent oxidation to the active metabolite. In contrast to clopidogrel, prasugrel requires only one CYP-P450 dependent metabolic step for activation. The antiplatelet effect of prasugrel is timeand dose-dependent. After an oral loading dose the antiplatelet effect is seen after 6090 min. After multiple dosing a steady state is reached after 24 days. Recovery of platelet function occurs between 48 hours and 7 days after discontinuation of therapy. Compared with clopidogrel, prasugrel resulted in faster and greater platelet inhibition. The variability was much less than that observed with clopidogrel. However, prasugrel was associated with a higher risk of bleeding than clopidogrel. In patients with acute coronary syndrome a loading dose of 60 mg prasugrel followed by 10 mg daily was more effective than a 300 mg loading dose of clopidogrel followed by 75 mg daily. The JUMBO-TIMI 26 trial demonstrated that the safety and efficacy of prasugrel is comparable to clopidogrel . In the TRITIN-TIMI 38 trial prasugrel was superior to clopidogrel for the primary endpoints death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in patients with coronary syndromes when compared with clopidogrel [Wiviott et al. 2007 ]. However, overall mortality was not different between the two groups. Importantly, risk for major bleeding has been increased, including fatal bleeding. The more profound effect of prasugrel on platelet aggregation is associated with a reduced rate of thrombotic events but it is also associated with a higher risk of bleeding. Very recently, prasugrel was approved by the FDA and EMEA for the treatment of patients with an acute coronary syndrome undergoing PCI. It must be concomitantly used with aspirin.
Cangrelor
Cangrelor is a new reversible P2Y 12 -receptor antagonist. In contrast to other thienopyridines, cangrelor is applied intravenously. It shows a rapid onset of action und as a result of reversible binding a rapid loss of action. This could improve the safety profile, especially in the setting of perioperative coronary surgery. Cangrelor has not been approved yet.
GP IIb/IIIa receptor antagonists
Of the many agonists that initiate platelet aggregation, aspirin or clopidogrel only block the specific stimulation by thromboxane or ADP, respectively, while other potent stimuli such as thrombin are not affected. Crosslinking of platelets by fibrinogen is the final common pathway that leads to the formation of an unstable primary thrombus. Fibrinogen binds to GP IIb/IIIareceptors on the platelet surface. The GP IIb/ IIIa-receptor-antagonists are a group of drugs that prevent the binding of fibrinogen to the GP IIb/IIIa-receptor and therefore block thrombus formation and stabilization. There are approximately 80,000 GP IIb/IIIa-receptors on a platelet's surface [Coller et al. 2008] . Platelet aggregation is completely abolished at approximately 80% receptor blockade whereas bleeding time is only weakly affected. However, if more than 90% of GP IIb/IIIa-receptors are blocked, bleeding time becomes extremely prolonged. To achieve optimal antiplatelet effect therapy with all GP IIb/IIIa-receptor-antagonist is started with a bolus followed by an infusion. The main indication for the use of GP IIb/IIIa-receptor-antagonists are patients undergoing PCI. Concurrent treatment with heparin and aspirin is obligatory.
Abciximab
Abciximab is a humanized Fab fragment of the monoclonal antibody 7E3, directed against GP IIb/IIIa-receptor [Ibbotson et al. 2003 ]. It has a high binding affinity and slow dissociation rate for the GP IIb/IIIa-receptor. Abciximab is an unspecific antibody that binds to inactivated and activated GP IIb/IIIa-receptors as well as to a few other integrins. After a bolus of 0.25 mg/kg approximately 60% of abciximab bind to platelets blocking more than 80% of platelet aggregation. This bolus is followed by a continuous infusion of 0.125 mg/kg/min for 12 hours. After its administration free abciximab concentration drops rapidly with a half-life of 30 min. This can be explained by its binding to the GP IIb/ IIIa-receptors and to albumin. Abciximab is metabolized by the reticuloendothelial system. The normal turnover rate of platelets is 10% per day. Therefore, 10 days after its administration no abciximab should be detectable in plasma. However, even after 3 weeks abciximab can be detected in plasma. The reason for this is the slow dissociation of abciximab from the GP IIb/IIIa-receptor and its switching from one platelet to another. Thus the antiplatelet effect lasts much longer than the half-life reflects. Platelet aggregation returns generally to baseline levels within 1224 hours after discontinuation of therapy. If platelet aggregation must be recovered more rapidly large amounts of platelets must be transfused to allow the redistribution of abciximab between platelets, thereby reducing the number of GP IIb/IIIa-receptors occupied by abciximab and restoring platelet aggregation. Concomitant application of abciximab with anticoagulants and/or other antiplatelet drugs is associated with increased bleeding. Abciximab is contraindicated in patients with active bleeding within the previous 30 days, or a history of bleeding diathesis, a history of stroke within 30 days, or any history of haemorrhage stroke; bleeding diathesis, thrombocytopaenia, known coagulopathy or platelet disorder, recent major surgery or trauma, history or symptoms of aortic dissection, acute pericarditis, cirrhosis or other clinically significant liver disease, severe uncontrolled hypertension, current or planned use of another parenteral GP IIb/IIIa-receptor-inhibitor. Allergic reactions have been reported in patients with abciximab.
Eptifibatide
Eptifibatide is a cyclic heptapeptide. Cyclization of the peptide endowes it with greater antiaggregant potency [Curran and Keating, 2005] . Eptifibatide is highly specific for the GP IIb/IIIareceptor and in contrast to abciximab does not cross-react with other integrins. The binding to the GP IIb/IIIa-receptor is reversible and eptifibatide competitively binds with fibrinogen for the GP IIb/IIIa-receptor. It is extensively metabolized and predominantly eliminated by the kidney. Patients with impaired renal function (creatinine clearance <60 ml/min) have an increased risk of bleeding. Bleeding time normalizes within 15 min after stopping eptifibatide infusion. The half-life is approximately 2.5 hours. After 4 hours 50% of platelet aggregation has been regained. Thrombocytopaenia was associated with the use of eptifibatide. In some patients it stimulates the immune system. The safety of reinfusion has not been thoroughly investigated. However, high levels of antibodies have been reported in patients who developed thrombocytopaenia after re-exposure to eptifibatide. Bleeding, particularly from vascular access after PCI sites, occurs frequently. Oropharyngeal, gastrointestinal, and genitourinary bleeding can also occur, and the frequency of thrombocytopaenia is equal to placebo. Concomitant application of eptifibatide with anticoagulants and/or other antiplatelet drugs is associated with increased bleeding. Eptifibatide is contraindicated in patients with active bleeding within the previous 30 days, or a history of bleeding diathesis, a history of stroke within the previous 30 days, or any history of haemorrhagic stroke, bleeding diathesis, thrombocytopaenia, known coagulopathy or platelet disorder, recent major surgery or trauma, history or symptoms of aortic dissection, acute pericarditis, cirrhosis or clinically significant liver disease, severe uncontrolled hypertension, current or planned use of another parenteral GP IIb/IIIa-receptorantagonist, dependence on haemodialysis. Eptifibatide should be used with caution in elderly patients because clearance might be reduced due to impaired renal function resulting in an increased risk of bleeding.
Tirofiban
Tirofiban is a nonpeptide that binds with high specificity to the GP IIb/IIIa-receptor [Menozzi et al. 2005] . In contrast to abciximab, tirofiban is only loosely bound to the GP IIb/IIIa-receptor. Because the binding affinity is low, tirofiban must be present in plasma in abundant amounts to prevent or displace competitively fibrinogen from the receptor. For this reason it is not possible to antagonize tirofiban with infusion of platelets. Tirofiban infusion must be stopped and after 4 hours platelet aggregation returns to normal. The plasma half-life of tirofiban is approximately 2 hours. The antiplatelet effect wears-off after 4 hours. In patients with renal impairment (creatinine clearance <30 ml/min) half-life of tirofiban increases by more than three-fold. The manufacturer recommends reducing normal dosage by 50%. In elderly patients and in patients with severe renal impairment, tirofiban accumulates and can increase the risk for bleeding. Reversible thrombocytopaenia has been reported in a small percentage of patients. The most common adverse drug event associated with tirofiban concomitantly used with heparin and aspirin was bleeding. Furthermore, nausea, fever, and headache were reported after treatment with tirofiban, aspirin and heparin. The risk for thrombocytopaenia was slightly increased with tirofiban and heparin compared with heparin alone. In rare cases hypersensitivity reactions have been reported with tirofiban. Tirofiban is contraindicated in patients with active bleeding within previous 30 days, or a history of bleeding diathesis, a history of stroke within 30 days, or any history of haemorrhage stroke, thrombocytopaenia, known coagulopathy or platelet disorder, recent major surgery or trauma, history or symptoms of aortic dissection, acute pericarditis, cirrhosis or clinically significant liver disease, severe uncontrolled hypertension, current or planned use of another parenteral GP IIb/IIIa receptor inhibitor.
Clinical use of GP IIb/IIIa-receptor-antagonists GP IIb/IIIa-receptor-antagonists are efficacious in patients undergoing PCI and for treatment of the acute coronary syndrome [Mandava et al. 2008] . All GP IIb/IIIa-receptor-antagonists reduce in combination with PCI the relative risk of the composite endpoint of death, myocardial infarction or urgent target vessel revascularization by 3050%. In the TARGET study, abciximab was compared with tirofiban in patients undergoing PCI for ACS or stable angina. By 30 days abciximab was superior to tirofiban with respect to the composite endpoint of death, nonfatal MI and urgent target vessel revascularization [Topol et al. 2001] . However, at 12-month follow-up there was no difference in the composite endpoint between the two GP IIb/IIIa-receptor-inhibitors [Mukherjee et al. 2005] . The difference at 30 days is most probably attributable to a suboptimal inhibition of platelet aggregation within the 2 hours after initiation of treatment with tirofiban. Measurement of platelet aggregation showed that a bolus of 10 mg/kg tirofiban blocked 6064% whereas abciximab blocked 9094% of platelet aggregation [Kabbani et al. 2002] . In more recent studies using an initial bolus of 25 mg/kg tirofiban blocked 90% of platelet aggregation . Based on the available data, in patients with stable or unstable coronary artery disease undergoing PCI tirofiban 25 mg/kg bolus + 0.15 mg/kg/min infusion is probably as effective as a standard dose of abciximab with a comparable safety profile [Mukherjee and Roffi, 2007] . Similar to tirofiban the dosage of the bolus of eptifibatide had to be increased as well to achieve predictable inhibition of platelet aggregation of more than 80%. A double bolus regime of 180 mg/kg eptifibatide 10 min apart followed by an infusion of 20 mg/kg/min has been shown to be optimal [Gilchrist et al. 2001] . In contrast to these beneficial effects, GP IIb/IIIa-receptorantagonists have only moderately improved the outcome in patients with NSTEMI with a relative risk reduction for death or myocardial infarction. High-risk patients, especially those with high levels of troponin, benefit substantially from GP IIb/IIIa-receptor-antagonists. In patients with NSTEMI not undergoing PCI the three receptor antagonists have been differently effective. Eptifibatide and tirofiban are safe but only weakly effective. Abciximab was associated with a worse clinical outcome. However, if patients undergo coronary intervention abciximab improves clinical outcome. Because antiplatelet effects wear off rapidly tirofiban is ideally suited for patients undergoing bypass surgery or PCI. For optimal therapeutic effects all GP IIb/IIIareceptor-antagonists must be combined with heparin and aspirin. Oral GP IIb/IIIa-receptorantagonists have also been developed; however, they were therapeutically ineffective or caused an increased risk of bleeding. The recently updated evidence-based guidelines of the American College of Cardiology/American Heart Association recommend the use of GP IIb/IIIareceptor-antagonists concomitantly with aspirin and heparin in patients with STEMI or UA/ NSTEMI undergoing PCI King et al. 2008; Anderson et al. 2007] . Clinical trials have shown that patients with high levels of troponin profit most from this treatment [Kwa and Rogers, 2008] .
Resistance to antiplatelet drugs
The term antiplatelet 'resistance' is used to describe different phenomena such as (1) inability to prevent thrombotic complications, (2) failure to inhibit platelet aggregation by in vitro platelet function tests, (3) insufficient inhibition of plasma or urinary biochemical markers for platelet aggregation [Smit and Van 'T Hof, 2007] . A recently published meta-analysis showed that aspirin-resistant patients are at greater risk of clinical important cardiovascular morbidity long term than patients who are sensitive to aspirin [Krasopoulos et al. 2008] . Interestingly, this analysis also showed that aspirin resistant patients did not benefit from other antiplatelet treatment. The different aspects of antiplatelet resistance have been reviewed extensively [Hankey and Eikelboom, 2006; Mason et al. 2005; Sanderson et al. 2005] . The variability to antiplatelet drugs is well documented in the large meta-analysis of the Antiplatelet Antithrombotic Trialist's collaboration [2002] . Nonresponsiveness to a certain drug is a common phenomenon in drug therapy and can have many different causes. A main problem of antiplatelet resistance is that there is no generally accepted definition of antiplatelet resistance. Furthermore, currently there are no standardized or uniformly accepted laboratory methods to measure antiplatelet resistance.
Assessment of platelet function
The rational for monitoring platelet function is treatment failure of antiplatelet drugs in patients with coronary heart disease. There are a number of different methods to assess the effect of antiplatelet drugs on platelet aggregation [Gurbel et al. 2007; Zeidan et al. 2007 ]. These methods are complex and confounded by many methodological factors such as the selection of the most appropriate stimulator for a specific antiplatelet drug. The variability of results obtained from different assays is large. For example, 545% of aspirin-treated patients are classified as nonresponders depending on the assay used [Fitzgerald, 2003] . Furthermore results from these platelet aggregation tests correlate poorly with clinical outcome for an individual patient.
No clinical study has examined whether dose adjustment according to laboratory findings can improve clinical outcome. Therefore, these methods are not recommendable to guide antiplatelet therapy in an individual patient. However, algorithms have been proposed for the management of antiplatelet therapy of patients with suspected antiplatelet resistance [Ang and Mahmud, 2008; Mahmud and Ang, 2006 ].
Resistance to aspirin
Aspirin resistance is a complex phenomenon including (1) the failure to protect individuals from the development of thrombotic complications, (2) the failure of aspirin to prolong bleeding time, (3) the failure of aspirin to inhibit arachidonic acid stimulated thromboxane A 2 formation (TxA 2 ) via platelet cyclo-oxygenase I, and (4) the failure to prevent arachidonic acid stimulated platelet aggregation in an ex-vivo platelet function test. Despite adequate treatment with aspirin about 10% (020%) of recurrent vascular events could be attributed to aspirin resistance [Hankey and Eikelboom, 2006 ]. This phenomenon of nonresponse is continuous and not an allor-nothing-response to aspirin. There are many causes of aspirin failure such as reduced bioavailability, polymorphism of COX I, alternative pathways of platelet activation, increased platelet turnover to name the most important [Hankey et al. 2006 ]. So far there is no single cause of aspirin resistance. Recently, noncompliance was identified as the major cause of aspirin resistance in patients undergoing PCI [Cuisset et al. 2009 ]. To overcome aspirin resistance higher dosages up to 325 mg have been suggested. However, this is associated with a higher bleeding risk [Gurbel and Tantry, 2006 ].
Resistance to clopidogrel
Similar to aspirin there are some patients who do not respond adequately to clopidogrel treatment despite adherence to therapy. In three landmark studies the basic mechanism of clopidogrel resistance has been at least in part unravelled. As a prodrug clopidogrel requires metabolism by CYP3A4 and CYP2D19 for full activation. In these studies it has been shown that polymorphism of CYP2C19 is pivotal for the metabolism of clopidogrel to its active moiety. In patients with CYP2C19*2 loss of function variants no active metabolite could be detected in plasma after normal dosage. Most importantly these alleles were associated with an increased risk of death from cardiovascular causes, myocardial infarction or stroke that was twice as high as in noncarriers. Furthermore, the risk was also increased in patients who underwent PCI [Simon et al. 2009 ]. In addition, the risk for stent thrombosis was more than three-fold increased compared to the rate of noncarriers [Collet et al. 2009 ]. Patients carrying any two CYP2C19 loss of function alleles (*2,*3,*4, or *5) had a higher event rate than patients with none [Simon et al. 2009 ]. Furthermore, patients with the genotype of TT or CT of ABCB1, the carrier molecule involved in the absorption of clopidogrel, had a higher risk for cardiovascular events, although the effects were less pronounced than those observed with the CYP2C19*2 loss of function variants. Previously, an interaction between clopidogrel and omeprazol has been proposed as a mechanism of reduced response to clopidogrel because both drugs share the metabolism by CYP 3A4. This could not be verified [Simon et al. 2009 ]. However, as the data basis is limited, such an interaction cannot be completely excluded. In summary, the elucidation and verification of CYP2C19 polymorphism as a primary cause of clopidogrel resistance is a major step forward to deal with this problem. At the very least, highrisk patients should be tested for genetic variants of CYP2C19. Because it is more rapidly metabolized to its active metabolite and this metabolism is independent from the polymorphism of CYP2C19 prasugrel is a useful alternative to clopidogrel in high-risk patients who are resistant to clopidogrel.
Resistance to the combination of aspirin and clopidogrel Despite concomitant treatment with aspirin and clopidogrel ischaemic events still occur in a significant percentage of patients. In a small study a group of patients undergoing PCI have been identified who were resistant to the dual combination of aspirin and clopidogrel [Lev et al. 2006] . Recently it has been reported that 6% of patients with a drug-eluting stent were resistant to the combination of aspirin and clopidogrel [Gori et al. 2008] .
Anticoagulants
Unfractionated heparin (UFH) Unfractionated heparin (UFH) is a mixture of polysaccharides with a molecular weight that ranges from 5000 to 30,000 Da with a mean of 15,000 Da . Heparin binds to antithrombin III (ATIII) through a pentasaccharide and induces a conformational change of the ATIII-molecule. This heparin-ATIII-complex inhibits thrombin (factor IIa) and factor Xa 100 to 1000 times stronger than ATIII alone. However, only one-third of UFH-molecules have this accelerating effect on ATIII. Once the ATIII-thrombin-complex has been formed heparin is released and can bind to a new ATIIImolecule. UFH inhibits thrombus formation but has no effect on existing thrombus. It can be applied subcutaneously or intravenously. UFH binds to endothelial cells, plasma proteins and macrophages to a variable extent. This unspecific binding of UHF causes highly variable plasma concentrations. Consequently the unpredictable doseresponse relationship and the small therapeutic index of UFH make close monitoring of the activated partial thromboplastine time (aPTT) mandatory. The dose of UFH should be adjusted to an aPTT value of 1.5 to 2.5 times the control. Higher aPTT values are associated with an increased risk of cerebral bleeding. Bleeding and heparin induced thrombocytopaenia (HIT) are the two major adverse reactions of heparin. To reduce the risk of HIT heparin should not be administered for more than 48 hours because thereafter the risk is greatly increased. Patients who have received UFH within the last 100 days are at an increased risk for HIT and therefore a baseline platelet count and a repeat platelet count within 24 hours of starting heparin treatment is highly recommended [Warkentin et al. 2009 ]. UFH was also associated with osteoporosis, alopecia and hypersensitivity. The main advantage of UFH is that its anticoagulant effect can be antagonized with protamine, although it should be recognized that protamine does not completely inhibit the effect of UFH because protamine does not interact with the low-molecular-weight fraction of UFH which comprises approximately 30% of the dose. In standard dosages UFH is not eliminated by the kidney and therefore dose adjustment in renal impairment is not necessary. The recently updated evidence-based guidelines of the American College of Cardiology/American Heart Association recommend the use of UFH for patients with STEMI , or UA/NSTEMI [Anderson et al. 2007 ] and those patients undergoing PCI [King et al. 2008] .
Low-molecular-weight heparin (LMWH)
Low-molecular-weight heparins (LMWHs) are derived from UFH by chemical and enzymatic depolymerization . Since the various LMWHs are prepared by different methods, they differ considerably with respect to their molecular weight, pharmacokinetic and dynamic properties . The different LMWHs are therefore not interchangeable! LMWHs inactivate factor Xa through the direct binding of the activated ATIII to factor Xa.
In contrast, inactivation of factor IIa requires the formation of a complex of thrombin, ATIII and heparin. To keep this complex together heparin requires a certain length. Only 2040% of the LMWHs are long enough to form this complex. For drug monitoring of LMWH only measurement of anti-factor-Xa is suitable. HIT is mainly caused by antibodies against a complex of platelet factor 4 (PF4) and heparin. As in contrast to UFH, LMWHs do not bind to PF4, the incidence of HIT associated with LMWHs is lower than with UFH. LMWHs are administered subcutaneously. In contrast to UFH, LMWHs do not bind to binding sites other than ATIII. Thus weight-based dosing of LMWHs results in predictable pharmacokinetics in normal kidney function and LMWHs are normally not monitored. In patients with different pharmacokinetics such as renal failure, obesity, newborns, and pregnancy monitoring of the anticoagulant effects of LMWHs with anti-factor-Xa is necessary. In contrast to UFH, LMWHs are nearly completely excreted by the kidney. In patients with a renal creatinine clearance of less than 30 ml/min the dosage must be adjusted according to the manufacturer. Bleeding and thrombocytopaenia are the most common adverse drug reactions. However, the risk of bleeding is lower than that with UFH. Thrombocytopaenia, skin necrosis, pain on injection site, elevation of serum aminotransferase levels, and oedema have been reported. Rash, fever and anaphylactoid reactions occur rarely. Patients with a hypersensitivity to heparin or pork products as well as patients with HIT should not be treated with LMWHs. The risk of bleeding is increased if LMWHs are concomitantly used with oral anticoagulants, antiplatelet drugs or fibrinolytics. LMWHs must not be administered intramuscularly.
Enoxaparin has a mean molecular weight of 4200 Da and a plasma half-life between 130 and 180 min [Fareed et al. 2003 ]. Peak antifactor-Xa occurs 35 hours after subcutaneous injection and persists for about 12 hours. A minor part of enoxaparin is metabolized in the liver but most of the drug is eliminated by the kidney. Dalteparin has a mean molecular weight of 6000 Da and a plasma half-life between 120 and 140 min [Dunn and Jarvis, 2000] . Peak antifactor Xa occurs after 2.8 to 4 hours. Dalteparin is deposited in the liver and in the kidney to a smaller extent than UFH. Dalteparin is mainly excreted by the kidney.
The recently updated evidence-based guidelines of the American College of Cardiology/American Heart Association recommend the use of enoxaparin for patients with UA/NSTEMI, STEMI with PCI King et al. 2008; Anderson et al. 2007 ]. Furthermore, they recommend the use of dalteparin in combination with aspirin for patients with UA/NSTEMI [Anderson et al. 2007 ].
Direct and indirect thrombin antagonists

Bivalirudin
Bivalirudin is a direct thrombin inhibitor that blocks thrombin-induced platelet activation and aggregation [Moen et al. 2005] . It binds like hirudin at both ends of thrombin without the need of any cofactor. In contrast to hirudin, which binds irreversibly, the binding of bivalirudin is transient. Bivalirudin binds to thrombin whether it is free or bound to fibrin. This is the major difference to heparin which binds to fibrin bound thrombin only poorly. It shows a linear pharmacokinetic and is therefore easy to handle. It is not significantly bound to plasma protein and does not interact with the CYP metabolism. It has no immunogenic potential in contrast to heparin. Elimination is dual: approximately 80% is degraded by proteolysis and 20% is directly excreted by the kidney. The half-life of bivalirudin is 25 min. Prothrombin time, INR, activated clotting time, activated partial thromboplastin time and thrombin time all rise linearly with increasing dosages of bivalirudin. Intravenous administration produces a rapid anticoagulation effect. The half-life is extended to 1 hour in severe renal impairment. In dialysis, half-life is approximately 4 hours. Dosage must be reduced and frequent monitoring is mandatory. There is no antidote available for bivalirudin although haemodialysis, haemofiltration and plasmapheresis can remove significant amounts of bivalirudin. Therapy is started with a bolus of 0.75 mg/kg followed by a continuous infusion. In comparison with LMWH bivalirudin is more effective and associated with less adverse effects like bleeding. The ecarin clotting time is the laboratory test of choice to monitor the antiplatelet effect of bivalirudin. In addition, in patients undergoing PCI bivalirudin plus provisional use of GP IIb/IIIa inhibitors (7%) was noninferior to heparin plus planned GP IIb/IIIa inhibition for the composite endpoint of death, MI revascularization or major bleeding, or for the composite endpoint of death, MI or revascularisation at 30 days [Moen et al. 2005] . Furthermore in combination with GP IIb/IIIa-receptor-antagonists it was similarly effective as heparin with GP IIb/ IIIa-receptor-antagonists, although bleeding rates were lower with bivalirudin. Bivalirudin is the only anticoagulant that reduces ischaemia similar to UFH and does not increase the risk for bleeding compared with UFH. However, bleeding is the major adverse effect of bivalirudin. It is more common in patients with renal impairment. Antigenicity is unlikely because bivalirudin is a small molecule. In 0.03% allergic reactions are seen. Safety of re-exposure has not been assessed. Crossreaction with lepirudin is possible. The recently updated evidence-based guidelines of the American College of Cardiology/American Heart Association recommend the use of UFH for the treatment of patients with UA/NSTEMI, STEMI undergoing PCI King et al. 2008; Anderson et al. 2007 ].
Fondaparinux
Fondaparinux is the first synthetic pentasaccharide that binds selectively to antithrombin III [Wienbergen and Zeymer, 2007] and is structurally related to the pentasaccharide moiety of UFH and LMWH. It inhibits factor Xa, thrombin generation, and thrombus formation. Its effect on factor Xa is seven-fold stronger than that of LMWH or UFH. However, fondaparinux inhibits thrombin activity not completely. Thus, this remaining thrombin activity is sufficient to maintain basic haemostasis within the injured area. In contrast to direct thrombin inhibitors, fondaparinux does not interact with the thrombomodulin/protein C-pathway. Thus the remaining thrombin activity is possibly of clinical importance because it could explain the lower risk for major bleeding in fondaparinux compared with enoxaparin. After subcutaneous administration the absorption is complete and maximal plasma concentrations are reached after 2 hours. The usual dose is 2.5 mg once daily [Anderson et al. 2007 ]. Because fondaparinux binds selectively and exclusively to ATIII, its plasma concentration is predictable. It has a long half-life of 17 hours. Thus, it can be used once a day without monitoring. It is not metabolized in the liver and is almost completely excreted as an unchanged molecule by the kidney. It accumulates in elderly patients and in patients with renal impairment and thus increases the risk for major bleeding. Protamine is ineffective as an antidote to fondaparinux; however, it has been shown that recombinant factor VII is able to reverse the anticoagulant effect of fondaparinux [Bijsterveld et al. 2002] . Frequency of thrombocytopaenia is similar to enoxaparin or dalteparin. There are no validated reports of HIT associated with fondaparinux [Bergqvist, 2006] . Thus it can be used in patients with HIT. It should be carefully used in patients with a body weight of less than 50 kg because of increased risk of bleeding. Bleeding is a major adverse reaction of fondaparinux; however, the risk of bleeding is significantly lower or comparable with enoxaparin. Constipation, headache, insomnia, nausea, fever, urinary tract infections and hypokalaemia were more frequent associated with fondaparinux than with enoxaparin. No drug interactions were observed between fondaparinux and warfarin, aspirin and NSAIDs. It is contraindicated in patients with severe renal impairment (creatinine clearance <30 ml/min). In addition, it is contraindicated in patients with active major bleeding, bacterial endocarditis, thrombocytopaenia associated with antiplatelet antibodies. The recently updated evidence-based guidelines of the American College of Cardiology/American Heart Association recommend the use of fondaparinux for the treatment of UA/NSTEMI [Anderson et al. 2007] . In comparison to enoxaparin it reduced not only major bleeding but also mortality. Fondaparinux is recommended in patients with bleeding risk and those with renal dysfunction. It should not be used in patients with STEMI undergoing PCI because it was ineffective and associated with more catheter thrombosis [Yusuf et al. 2006 ].
